BMC Infectious Diseases (Dec 2009)

A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentation

  • Parry Christopher,
  • My Phan,
  • Boni Maciej F,
  • Hoang Nguyen,
  • Campbell James I,
  • Duy Pham,
  • Nga Tran,
  • Nhu Nguyen,
  • Vinh Ha,
  • Nga Tran,
  • Van Minh Pham,
  • Thuy Cao,
  • Diep To,
  • Phuong Le,
  • Chinh Mai,
  • Loan Ha,
  • Tham Nguyen,
  • Lanh Mai,
  • Mong Bui,
  • Anh Vo,
  • Bay Phan,
  • Chau Nguyen,
  • Farrar Jeremy,
  • Baker Stephen

DOI
https://doi.org/10.1186/1471-2334-9-204
Journal volume & issue
Vol. 9, no. 1
p. 204

Abstract

Read online

Abstract Background Shigellosis remains considerable public health problem in some developing countries. The nature of Shigellae suggests that they are highly adaptable when placed under selective pressure in a human population. This is demonstrated by variation and fluctuations in serotypes and antimicrobial resistance profile of organisms circulating in differing setting in endemic locations. Antimicrobial resistance in the genus Shigella is a constant threat, with reports of organisms in Asia being resistant to multiple antimicrobials and new generation therapies. Methods Here we compare microbiological, clinical and epidemiological data from patients with shigellosis over three different periods in southern Vietnam spanning14 years. Results Our data demonstrates a shift in dominant infecting species (S. flexneri to S. sonnei) and resistance profile of the organisms circulating in southern Vietnam. We find that there was no significant variation in the syndromes associated with either S. sonnei or S. flexneri, yet the clinical features of the disease are more severe in later observations. Conclusions Our findings show a change in clinical presentation of shigellosis in this setting, as the disease may be now more pronounced, this is concurrent with a change in antimicrobial resistance profile. These data highlight the socio-economic development of southern Vietnam and should guide future vaccine development and deployment strategies. Trial Registration Current Controlled Trials ISRCTN55945881